Follow-Up Care for Congenital CMV-Positive Babies After Birth

Immediate Baseline Evaluation

All infants with confirmed congenital CMV infection require comprehensive multidisciplinary evaluation soon after identification, with mandatory baseline assessments by infectious disease, audiology, ophthalmology, otolaryngology, and speech-language pathology, followed by serial audiological monitoring every 4-6 months through at least age 2 years, due to the high risk of progressive or late-onset hearing loss 1, 2
The American Academy of Otolaryngology-Head and Neck Surgery recommends that all CMV-positive infants need baseline assessments soon after diagnosis, including infectious disease specialist, audiology, ophthalmology, otolaryngology, and speech-language pathology 1, 2, 3

For symptomatic congenital CMV disease, a 6-month course of valganciclovir modestly improves developmental outcomes at 2 years and has protective effects on hearing thresholds to prevent progression of hearing loss 1, 2, 3
A 6-month course of valganciclovir is superior to 6 weeks for developmental outcomes in symptomatic infants 1, 2, 3

Serial hearing evaluations are critical because hearing loss can be progressive or have late onset, with assessments every 4-6 months through at least age 2 years, often extending beyond 1, 2
Parents should be counseled to report any new hearing concerns immediately without waiting for scheduled visits 1, 2
Even slight/mild degrees of hearing loss may compromise auditory access to speech and language cues 1, 2, 3

All infants should be monitored for developmental delays, learning disabilities, and other neurological sequelae 4
Approximately 10-15% of asymptomatic infants at birth develop later developmental abnormalities, sensorineural hearing loss, chorioretinitis, or neurologic defects 4

Full-time use of well-fit hearing technology is recommended for all children who are candidates, whether for unilateral or bilateral hearing loss 1, 2, 3
Hearing aids are recommended for mild to moderate hearing loss, to amplify incoming signals to detectable levels 1, 2, 3
Cochlear implants are recommended for moderately severe or worse hearing loss when insufficient residual hearing exists to benefit from hearing aids 1, 2, 3

CMV testing must be performed within the first 21 days of life to distinguish congenital from acquired postnatal infection 5
Do not assume asymptomatic infants at birth will remain unaffected - 10-15% develop sequelae later 4
Hearing loss and other manifestations may have late onset or be progressive, requiring long-term surveillance 1, 2

The Centers for Disease Control and Prevention recommends beginning antiviral therapy as soon as congenital CMV is confirmed, ideally in the neonatal period, with valganciclovir or intravenous ganciclovir as alternative, for a duration of 6 months 6, 7
Alternative antiviral treatment with intravenous ganciclovir 6 mg/kg every 12 hours can be used if oral administration is not feasible, though valganciclovir is preferred for outpatient management, according to the CDC guidelines 6, 7

The CDC advises against delaying treatment initiation while awaiting subspecialty consultations, as early neonatal treatment provides optimal benefit, and recommends a 6-month course of antiviral therapy 6, 7
Dose modification may be required in patients due to neutropenia; granulocyte colony-stimulating factor can be used for severe cases, as recommended by the CDC 6, 7